Impedimed perking up

SHARES in Brisbane medical device maker Impedimed revived 8.5¢ to 70¢ yesterday after it obtained a CE Mark for its new Sozo technology, clearing a European regulatory hurdle.

Impedimed’s technology measures changes in patient fluid levels, and the CE Mark covers its use in the newly planned market of heart failure. The classification also covers Sozo in assessing a swelling ailment linked to cancer, using Impedimed’s L-Dex tool, and hydration monitoring.

“Obtaining CE Mark for multiple indications for the Sozo platform (enables) us to now make Sozo commercially available to physicians and patients throughout Europe and Australia,” Impedimed said.

While the stock hit 70¢, it is still down on last year’s highs of $1.82, having fallen amid concerns about delays to the release of some trial data.